Plate-Based Pharmacology
At EnquBio, our Plate-Based Pharmacology capabilities are among the finest in the industry, powered by seasoned experts with over 15 years of proven success and a reputation for excellence. We offer assays across all major therapeutic areas and target classes, with scalable formats up to 1536-well plate screening for maximum efficiency and data quality. Our state-of-the-art HTS and SAR platforms deliver a seamless, data-driven workflow, from compound management and innovative assay development to precision data analysis, enabling faster, smarter, and more reliable discovery outcomes.
EnquBio provide centralized compound management to support global in-vitro pharmacology operations, including logistics, storage, cherry-picking, QC, and data tracking. Our integrated system ensures seamless information flow from client request to final data, eliminating manual steps. Services include compound receiving, registration, storage, and HTS-ready plate preparation, supported by automated instrumentation and regular QC verification.
High- throughput Screening (HTS)
Our HTS platform is built on over 15 years of industry expertise and is supported by a fully integrated infrastructure combining advanced automation, data tracking, and assay development. We offer scalable screening formats (384- and 1536-well plates) and fast assay onboarding—2–3 weeks for biochemical assays and 4–6 weeks for cell-based assays. Backed by a comprehensive set of readers (including EnVision, FLIPR, and Operetta) and custom reporting solutions (Excelfit, Abase, Genedata), we deliver high-quality, data-driven insights to accelerate hit identification and lead optimization.
Hit- to- Lead & Lead Optimization
Our in vitro pharmacology platform features a highly experienced team and a well-integrated HTS and SAR infrastructure to accelerate drug discovery. We support rapid assay development (2–3 weeks for biochemical, 4–6 weeks for cell-based) and high-throughput screening using 384 or 1536-well formats. With secure backup plans, automated compound handling, and customized data reporting (Excelfit, Abase, Genedata), we ensure efficient and reliable lead progression from assay to SAR cycles in as little as 24 hours.
Assay Development
We offer a complete in vitro platform for custom cell line generation and assay development. Our experienced team routinely delivers stable overexpression, KO/KI, and CRISPR-modified cell lines within ~6 weeks. Standardized cell-based assay packages—including assessments of potency, uniformity, and stability—are developed in ~2 months. Large-scale cell banking and QC ensure reproducibility for screening campaigns. Our off-the-shelf GPCR assay portfolio includes validated cAMP, β-arrestin, and internalization assays for GLP-1R, GIPR, and GCGR, supporting lead optimization in obesity and diabetes research.
Our fully automated High Content Screening (HCS) platform enables large-scale identification of drug targets and lead compounds. With standardized SOPs and week-to-week data consistency, HCS supports rapid hit discovery and reliable phenotypic profiling. We offer a wide range of readouts including apoptosis, DNA damage, hepatotoxicity, autophagy, protein aggregation, and more. The system is compatible with tumor cell lines, iPSC-derived cells, and primary cells, providing multiparametric data from complex biological models to support informed go/no-go decisions early in drug discovery.